![conference banner](/images/conference-banner.jpeg)
Abstract
Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobioticmetabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and / or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Although the use of the term “xenobiotic” implies that XME form a separate and distinct class of enzymes, possible endogenous substrates may exist. Unlike NAT2, NAT1 is produced in most tissues. Polymorphism at the NAT1 locus has been associated with the existence of at least 26 allelic variants, generating phenotypic variations in terms of NAT1 catalytic activity. This genetic variation affects the acetylator status of individuals, leading to interindividual differences in drug response and predisposition to disease in humans. Recent studies have shown that non-genetic factors may also regulate NAT1 activity at the posttranslational level, with potentially important consequences for drug toxicity. In this minireview, we summarise what is currently known about the regulation of NAT1 activity by non-genetic factors, including substrates and oxidative stress. Recent findings presented here may account for the genotype / phenotype relationship for the NAT1 locus being less clear-cut than that for human NAT2.
Keywords: n-acetyltransferase, xenobiotics, polymorphism, catalytic activity, regulation, inherited factors, oxidative stress, enzyme inactivation
Current Pharmaceutical Design
Title: Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors
Volume: 10 Issue: 20
Author(s): Fernando Rodrigues-Lima and Jean-Marie Dupret
Affiliation:
Keywords: n-acetyltransferase, xenobiotics, polymorphism, catalytic activity, regulation, inherited factors, oxidative stress, enzyme inactivation
Abstract: Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobioticmetabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and / or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Although the use of the term “xenobiotic” implies that XME form a separate and distinct class of enzymes, possible endogenous substrates may exist. Unlike NAT2, NAT1 is produced in most tissues. Polymorphism at the NAT1 locus has been associated with the existence of at least 26 allelic variants, generating phenotypic variations in terms of NAT1 catalytic activity. This genetic variation affects the acetylator status of individuals, leading to interindividual differences in drug response and predisposition to disease in humans. Recent studies have shown that non-genetic factors may also regulate NAT1 activity at the posttranslational level, with potentially important consequences for drug toxicity. In this minireview, we summarise what is currently known about the regulation of NAT1 activity by non-genetic factors, including substrates and oxidative stress. Recent findings presented here may account for the genotype / phenotype relationship for the NAT1 locus being less clear-cut than that for human NAT2.
Export Options
About this article
Cite this article as:
Rodrigues-Lima Fernando and Dupret Jean-Marie, Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors, Current Pharmaceutical Design 2004; 10 (20) . https://dx.doi.org/10.2174/1381612043383845
DOI https://dx.doi.org/10.2174/1381612043383845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Platelets in Cardiovascular Disease: Molecular Mechanisms
Current Pharmaceutical Design The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design The Role of Pharmaceutical Agents in the Alleviation of Male Infertility (Part-I)
Current Pharmaceutical Design Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Effect of Environmental Conditions on the Expression Levels of a Recombinant 11S Amaranth Globulin in Escherichia coli
Recent Patents on Biotechnology The Role of the Heme Oxygenase System in the Metabolic Syndrome
Current Pharmaceutical Design Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1
Current Hypertension Reviews Pharmacokinetics-based Chronotherapy
Current Drug Metabolism Predicting the Activity of ACE Inhibitory Peptides with a Novel Mode of Pseudo Amino Acid Composition
Protein & Peptide Letters Nanosystems for Skin Delivery: From Drugs to Cosmetics
Current Drug Metabolism Therapeutic Peptides: Unravelling Conformational Dynamics by Systematic Application of Biophysical Techniques
Current Protein & Peptide Science Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition